Actively Recruiting

Age: 14Years +
All Genders
ID03001947

IgA Nephropathy Registration Initiative of High Quality (INSIGHT)

Led by Sun Yat-sen University · Updated on 2020-10-22

10000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are creating a registry and database for patients in China diagnosed with biopsy-confirmed primary IgA nephropathy (IgAN). The study aims to collect detailed patient information and follow these patients annually to assess important health outcomes such as overall mortality, cardiovascular death, and kidney function decline leading to serious kidney failure. Participants include patients with biopsy-proven primary IgAN. The study involves registering patients from multiple hospitals and collecting baseline data including demographics, clinical status, lab tests, complications, and medication use. Follow-up visits occur yearly to update this information and record clinical events like hospitalizations, deaths, and kidney failure requiring dialysis or transplantation. Participants will be followed for up to 10 years, with annual assessments of their health status and kidney function. The research team will analyze the database to compare rates of death and kidney disease progression among IgAN patients. This observational study does not involve experimental treatments and focuses on detailed long-term data collection to better understand disease outcomes.

CONDITIONS

Brief Title

IgA Nephropathy Registration Initiative of High Quality (INSIGHT)

Who Can Participate

Age: 14Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Biopsy-proven primary IgA nephropathy patients
  • Age 14 years or older
  • Adequate kidney biopsy sample containing at least 8 glomeruli
Not Eligible

You will not qualify if you...

  • Secondary causes of mesangial IgA deposition, such as Henoch-Schonlein purpura nephritis, systemic lupus erythematosus, or liver cirrhosis
  • Estimated glomerular filtration rate (eGFR) less than 15 ml/min/1.73 m2 at biopsy

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Surveillance

Duration - Up to 10 years

Participants who undergo routine care are observed and their demographic and clinical characteristics, complications, drug information, and clinical events are collected.

Annual visits

Trial Site Locations

Total: 1 location

1

The First Affiliated Hospital, Sun Yat-Sen University

Guangzhou, Guangdong, China, 510080

Actively Recruiting

Loading map...

Research Team

X

Xueqing Yu, M.D. & Ph.D

Q

Qiongqiong Yang, M.D. & Ph.D

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

A Phase 1, Randomized, Double-blind, Placebo-controlled, Sin...

IgA Nephropathy

Actively Recruiting

1 location

A Phase 2, Multicenter, Open-label Study to Evaluate the Saf...

IgA Nephropathy

Actively Recruiting

7 locations

A Phase II Clinical Study Evaluating the Efficacy and Safety...

IgA Nephropathy

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here